Alkem Laboratories Ltd

Alkem Laboratories Ltd has received favorable Orders-in-Appeal from the Commissioner of Income Tax (Appeals) – 47, Mumbai, concerning assessment years 2018-19 to 2022-23. The statutory authority deleted disallowances made under Section 80-IE of the Income-tax Act, 1961, involving a tax amount of ₹660.77 Crores. The company stated that there is no material impact on its financial, operational, or other activities. The orders were received on June 30, 2026.

Alkem Laboratories Ltd, through its wholly owned subsidiary Alkem Medtech Private Limited, has executed a First Supplementary Agreement to the Share Purchase Agreement dated March 6, 2026, concerning the acquisition of Occlutech Holding AG. This follows earlier intimations regarding Alkem Medtech's intent to acquire between 51% and 55% of Occlutech's equity share capital. The supplementary agreement was executed on June 26, 2026, with the selling shareholders of the Swiss-incorporated Occlutech. Further details will be available on the company's website.

Alkem Laboratories Ltd has announced the closure of its trading window from June 29, 2026, until 48 hours after the communication of its financial results for the quarter ended June 30, 2026. This measure is in accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders. The closure is a standard procedure to prevent potential insider trading ahead of the announcement of financial performance.

Samprada & Nanhamati Singh Family Trust has disclosed a reduction in its shareholding in Alkem Laboratories Ltd. The Trust sold 0.46% of its stake, decreasing its total holding from 18.74% to 18.28%. This disclosure is in compliance with SEBI regulations regarding substantial acquisitions and takeovers, requiring trusts to report changes in trustees, beneficiaries, and share ownership. The sale consideration received has been distributed to the beneficiaries of the trust.

Alkem Laboratories has become the first company in India to launch semaglutide in single-shot pre-filled syringes, with prices starting at INR 350. This new delivery format aims to make the treatment more accessible and affordable for patients managing Type 2 diabetes and obesity. The company has received approval from the DCGI for these pre-filled syringes. Alkem had previously launched semaglutide injection pens in March 2026 and plans to launch vials soon. This move is expected to widen treatment options and improve patient adherence to therapy.

Alkem Laboratories Limited announced that its financial results for the quarter and year ended March 31, 2026, have been communicated to the stock exchanges on May 28, 2026. Following this communication, the trading window, which was previously closed, will now open on June 1, 2026. This update follows an earlier communication regarding the closure of the trading window from March 30, 2026, until 48 hours after the results' disclosure.

The Board of Directors approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹10 per equity share for FY26, subject to shareholder approval at the upcoming 52nd Annual General Meeting (AGM) on August 27, 2026. The record date for the final dividend payment has been fixed as August 7, 2026, with payment commencing from September 1, 2026, if declared. The cut-off date for the AGM is August 20, 2026. Additionally, the Board approved the re-appointment of Mrs. Madhurima Singh as an Executive Director for a term of five years, effective from December 20, 2026.

The Board of Directors of 539523 (Alkem Laboratories Limited) approved the standalone and consolidated audited financial results for Q4 and FY ended March 31, 2026. The Board recommended a final dividend of ₹10 per equity share (₹2 each) for FY26, subject to shareholder approval at the 52nd AGM on August 27, 2026. The record date for the dividend is August 7, 2026, with payment from September 1, 2026. Additionally, Mrs. Madhurima Singh's re-appointment as Executive Director for five years from December 20, 2026, was approved, subject to shareholder consent. The auditors expressed an unmodified opinion on the financial results.

Alkem Laboratories Limited's Board of Directors, at its meeting on May 28, 2026, approved the reappointment of Mrs. Madhurima Singh as an Executive Director. The new term will be for five consecutive years, commencing from December 20, 2026, and concluding on December 19, 2031. This decision was based on the recommendations from the Nomination and Remuneration Committee and the Audit Committee. The reappointment is contingent upon the approval of shareholders at the company's forthcoming Annual General Meeting, ensuring continuity in the company's executive leadership.

Alkem Laboratories Limited's Board of Directors, at their meeting on May 28, 2026, approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026. The Board recommended a final dividend of ₹10 per equity share (of ₹2/- each) for FY26, subject to shareholder approval at the 52nd Annual General Meeting (AGM) scheduled for August 27, 2026. The record date for the dividend payment is August 7, 2026, with payment commencing September 1, 2026, if declared. Additionally, Mrs. Madhurima Singh was approved for re-appointment as an Executive Director for five years, effective December 20, 2026.